Adipocytes As Anticancer Drug Delivery Depot
Di Wen,Jinqiang Wang,George Van Den Driessche,Qian Chen,Yuqi Zhang,Guojun Chen,Hongjun Li,Jennifer Soto,Ming Liu,Masao Ohashi,Zejun Wang,Peter Abdou,Quanyin Hu,Gianpietro Dotti,Song Li,Denis Fourches,Zhen Gu
DOI: https://doi.org/10.1016/j.matt.2019.08.007
2019-01-01
Abstract:Tumor-associated adipocytes promote tumor growth by providing energy and causing chronic inflammation. Here, we have exploited the lipid metabolism to engineer adipocytes that serve as a depot to deliver cancer therapeutics at the tumor site. Rumenic acid (RA), as an anticancer fatty acid, and a doxorubicin prodrug (pDox) with a reactive oxygen species (ROS)-cleavable linker, are encapsulated in adipocytes to deliver therapeutics in a tumor-specific bio-responsive manner. After intratumoral or postsurgical administration, lipolysis releases the RA and pDox that is activated by intracellular ROS-responsive conversion, subsequently promoting antitumor efficacy. Furthermore, downregulation of PD-L1 expression is observed in tumor cells, favoring the emergence of CD4(+) and CD8(+) T cell-mediated immune responses.